41 completed, 21 recruiting, 15 terminated, 8 active not recruiting. 43 Phase 2, 33 Phase 1, 6 Not applicable, 5 Early Phase 1, 4 Phase 3.
Follow Chronic Lymphocytic Leukemia (CLL): new trials by email Literature Review of Chronic Lymphocytic Leukemia (CLL) trials Research Report on Chronic Lymphocytic Leukemia (CLL)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Roginolisib Plus Obinutuzumab + Venetoclax in R/R CLL Roginolisib, Obinutuzumab, Venetoclax - Chronic Lymphocytic Leukemia (CLL), Refractory Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Not yet recruiting | Dana-Farber Cancer Institute | 40 | 2027-01-13 | 2026-09-29 |
| Innovative 3D Preclinical Models for Mature B-cell Malignancies to Advance Personalized Immuno and Combination Therapies Chronic Lymphocytic Leukemia (CLL), Splenic Marginal Zone Lymphoma | Not yet recruiting | IRCCS San Raffaele | 64 | 2026-11-01 | 2026-08-13 | |
| Epcoritamab as Consolidation Therapy for High-Risk Pts w/CLL on BTKI Epcoritamab - CLL, CLL (Chronic Lymphocytic Leukemia) | Phase 2 | Not yet recruiting | University of California, Irvine | 24 | 2026-10-01 | 2026-09-14 |
| Targeting IRAK4 in Chronic Lymphocytic Leukemia Peripheral blood sample collection - Chronic Lymphocytic Leukemia (CLL) | Not yet recruiting | IRCCS San Raffaele | 50 | 2026-09-01 | 2026-08-04 | |
| A Phase 2 Trial Of The Bruton Tyrosine Kinase Degrader BGB-16673 In Combination With BCL-2 Inhibitor Sonrotoclax For Patients With Treatment-Naive Chronic Lymphocytic Leukemia (CLL) BGB-16673, BGB-11417 - Chronic Lymphocytic Leukemia (CLL) | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 40 | 2026-08-20 | 2026-10-29 |
| Connected Blood Pressure Monitoring in Patients With Hematologic Malignancies Initiating Covalent BTK Inhibitors Connected home blood pressure monitoring with daily IPA supervision. - Chronic Lymphocytic Leukemia (CLL), Follicular Lymphoma ( FL) | Not applicable | Not yet recruiting | Centre Hospitalier de la côte Basque | 40 | 2026-07-01 | 2026-06-22 |
| MAVRiC Studies 2L Treatment With AV in Patients With CLL/SLL Who Have Relapsed After a Course of BTKi + BCL2i Combination, With or Without Obinutuzumab Acalabrutinib, Venetoclax - Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) | Phase 2 | Recruiting | AstraZeneca | 80 | 2026-06-04 | 2026-10-23 |
| Precision Physical Exercise for Personalized Onco-Hematology. Supervised Intervention, Home-based Intervention - Hematologic Cancer, Colon Cancer | Not applicable | Not yet recruiting | University of Salamanca | 150 | 2026-04-01 | 2025-12-16 |
| Immune Profiling of CLL/SLL Treated With First-Line Pirtobrutinib Pirtobrutinib - Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) | Early Phase 1 | Recruiting | National Heart, Lung, and Blood Institute (NHLBI) | 30 | 2026-03-11 | 2026-10-22 |
| Ibrutinib Plus Venetoclax Long-Term Outcomes in CLL Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) | Recruiting | European Research Initiative on CLL | 323 | 2025-12-18 | 2026-08-19 | |
| Impact of Targeted Therapy on Cancer-Related Cognitive Impairment Disease/Condition Name Cancer-related Cognitive Dysfunction, Chronic Lymphocytic Leukemia (CLL) | Recruiting | University of Rochester NCORP Research Base | 400 | 2025-11-21 | 2026-06-10 | |
| A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201) NX-5948 - Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) | Phase 2 | Recruiting | Nurix Therapeutics, Inc. | 100 | 2025-10-15 | 2026-11-03 |
| Clinico-hematological and Molecular Characteristics of Chronic Lymphocytic Leukemia Patients 1 Complete blood picture (CBC) with blood film, lymphocytic count 2 and viral hepatitis 3 Immunophenotyping 4 LDH 5 Coomb's tests ,deletion 17p,IGVH mutation,ESR - Chronic Lymphocytic Leukemia (CLL) | Not yet recruiting | Assiut University | 45 | 2025-10-01 | 2025-09-09 | |
| A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia GT801 Injection - B-cell Acute Lymphoblastic Leukemia (B-ALL), Chronic Lymphocytic Leukemia (CLL) | Early Phase 1 | Recruiting | Grit Biotechnology | 28 | 2025-09-26 | 2026-07-20 |
| Role of SF3B1 Mutation in Assessment of Acute and Chronic Lymphatic Leukemia Acute Lymphoblastic Leukemia ALL, Chronic Lymphocytic Leukemia (CLL) | Not yet recruiting | Safaa Ali | 84 | 2025-08-01 | 2025-08-08 | |
| Predictors of Health-Related QOL in Adults With CLL or Small Lymphocytic Lymphoma Bruton's tyrosine kinase inhibitor, B-Cell Lymphoma 2 Protein Inhibitor - Small Lymphocytic Lymphoma (SLL), Chronic Lymphocytic Leukemia (CLL) | Recruiting | H. Lee Moffitt Cancer Center and Research Institute | 100 | 2025-07-17 | 2026-04-01 | |
| A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies UB-VV111, rapamycin - Lymphoma, B-Cell, Lymphoma, Non-Hodgkin (NHL) | Phase 1 | Recruiting | Umoja Biopharma | 106 | 2025-03-10 | 2026-10-15 |
| A Study of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting Lisocabtagene maraleucel - Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) | Recruiting | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | 300 | 2025-02-04 | 2025-02-24 | |
| Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms Routine care as per site standard. - Chronic Lymphocytic Leukemia (CLL), Diffuse Large B-cell Lymphoma (DLBCL) | Recruiting | iOMEDICO AG | 2950 | 2023-09-27 | 2026-07-13 | |
| A Case Crossover Study of Intermittent Fasting in CLL/SLL 5:2 Method (intermittent fasting regimen), 16/8 Method (intermittent fast regimen) - Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) | Not applicable | Completed | British Columbia Cancer Agency | 6 | 2023-06-12 | 2024-03-08 |
Showing 20 of 102. Sign in to see all of them.
Leukemia, Lymphocytic, Chronic, B-Cell (102) · Lymphoma, Non-Hodgkin (21) · Lymphoma, Mantle-Cell (15) · Lymphoma, B-Cell, Marginal Zone (14) · Lymphoma, Follicular (14) · Lymphoma, Large B-Cell, Diffuse (14) · Leukemia, Myeloid, Acute (12) · Neoplasms (12) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (12) · Waldenstrom Macroglobulinemia (10) · Leukemia (9) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (9) · Lymphoma (9) · Recurrence (9) · Hematologic Neoplasms (8)
Chronic Disease (102) · Disease Attributes (102) · Hematologic Diseases (102) · Hemic and Lymphatic Diseases (102) · Immune System Diseases (102) · Immunoproliferative Disorders (102) · Neoplasms by Histologic Type (102) · Pathologic Processes (102) · Pathological Conditions, Signs and Symptoms (102) · Leukemia, Lymphoid (101) · Lymphatic Diseases (101) · Lymphoproliferative Disorders (100) · Leukemia, B-Cell (95) · Leukemia (93) · Neoplasms (90)
venetoclax (17) · Rituximab (9) · Bendamustine Hydrochloride (8) · obinutuzumab (8) · ibrutinib (5) · ofatumumab (5) · Cyclophosphamide (4) · acalabrutinib (4) · fludarabine (4) · idelalisib (4) · Lenalidomide (3) · zanubrutinib (3) · Sirolimus (2) · TRU 016 (2) · fludarabine phosphate (2)
AbbVie (11) · National Heart, Lung, and Blood Institute (NHLBI) (5) · Gilead Sciences (4) · Memorial Sloan Kettering Cancer Center (4) · Dana-Farber Cancer Institute (3) · Nurix Therapeutics, Inc. (3) · University of Rochester (3) · Aptevo Therapeutics (2) · Baylor College of Medicine (2) · Calibr, a division of Scripps Research (2) · IRCCS San Raffaele (2) · MEI Pharma, Inc. (2) · Nevada Cancer Institute (2) · Novartis Pharmaceuticals (2) · iOMEDICO AG (2)
United States (70) · Italy (11) · Poland (7) · Spain (7) · Australia (6) · Germany (5) · United Kingdom (5) · Austria (4) · China (4) · France (4) · Russia (4) · Canada (3) · Israel (3) · Japan (3) · Switzerland (3)
Mark Kirschbaum, MD (2) · Meghan Thompson, MD (2) · Scott Stromatt, MD (2) · Alex Young (1) · Alexey V Danilov, MD (1) · Andre Goy, MD (1) · Andrew Zelenetz, MD, PhD (1) · Asher Chanan-Khan, MD (1) · Bronwen E. Shaw, MD, PhD (1) · Carla Casulo, MD (1)
PMID 34398557, PMID 36375120, PMID 41843779, PMID 15728813, PMID 21812019, PMID 21816833, PMID 24030379, PMID 24381226, PMID 24615776, PMID 24615777, PMID 24615778, PMID 24733536, PMID 25146490, PMID 25486127, PMID 25734008, PMID 26472751, PMID 27222473, PMID 28126927, PMID 29420116, PMID 29463563, PMID 30069704, PMID 31151984, PMID 31314918, PMID 31352850, PMID 32383192, PMID 33259596, PMID 33905264, PMID 34515338, PMID 34534514, PMID 34632935, PMID 34826411, PMID 35127522, PMID 35157769, PMID 35254001, PMID 35597752, PMID 35835137, PMID 36689726, PMID 37729613, PMID 37877800, PMID 38143760, PMID 38421404, PMID 39167348, PMID 39437708, PMID 39509142, PMID 39645236, PMID 39705540, PMID 39719040, PMID 40163793, PMID 40552139, PMID 40809193
2023 (3), 2009 (1), 2016 (1), 2019 (1), P30CA060553 (1), R01CA177292 (1), R01CA266298 (1), R01CA287666 (1), UG1CA189961 (1)